4 Stocks Raising The Health Care Sector Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 22 points (-0.2%) at 14,556 as of Monday, April 1, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 762 issues advancing vs. 2,184 declining with 121 unchanged.

The Health Care sector currently sits down 1.1% versus the S&P 500, which is down 0.6%. A company within the sector that increased today was Celgene Corporation ( CELG), up 1.0%. On the negative front, top decliners within the sector include Vertex Pharmaceuticals ( VRTX), down 1.6%, Thermo Fisher Scientific ( TMO), down 1.3%, Gilead ( GILD), down 1.1%, Aetna ( AET), down 1.2% and Zimmer Holdings ( ZMH), down 0.9%.

TheStreet Ratings group would like to highlight 4 stocks pushing the sector higher today:

4. Dr. Reddy Laboratories ( RDY) is one of the companies pushing the Health Care sector higher today. As of noon trading, Dr. Reddy Laboratories is up $0.57 (1.8%) to $32.92 on heavy volume Thus far, 271,213 shares of Dr. Reddy Laboratories exchanged hands as compared to its average daily volume of 215,200 shares. The stock has ranged in price between $32.78-$33.76 after having opened the day at $33.50 as compared to the previous trading day's close of $32.35.

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. Dr. Reddy Laboratories has a market cap of $5.5 billion and is part of the drugs industry. The company has a P/E ratio of 19.6, above the S&P 500 P/E ratio of 17.7. Shares are down 2.9% year to date as of the close of trading on Thursday. Currently there is 1 analyst that rates Dr. Reddy Laboratories a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Dr. Reddy Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Dr. Reddy Laboratories Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you liked this article you might like

Generics Drop Across Board as DOJ Inquiry Expands

Teva Divests More Assets to Win EC Approval for Allergan Generics Deal

Changing Landscape for Generic-Drug Makers Creates Opportunities

Dr Reddy's Laboratories (RDY) Highlighted As Weak On High Volume

Ex-Dividend Alert: 3 Stocks Going Ex-Dividend Tomorrow: GLV, GLO, RDY